Actually there a great deal of studies which have reported the presence of anti-p53 antibodies to be an indicator of diagnosis or poor prognosis in patients with bladder [42], [43], hepatocellular carcinoma [44]–[49], head and neck cancer [50]–[53], pancreatic [54]–[57]. This evidence concerns the gene TP53 and hepatocellular carcinoma.